SEQSTER Expands Partnership with Praxis to Accelerate CNS Clinical Trials

Healthcare Technology / CNS San Diego & Boston | February 4, 2026

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Partnership Snapshot

• Tech Lead: SEQSTER
• Biopharma Lead: Praxis
• Focus: CNS Disorders
• Key Program: ENERGY (Epilepsy)
• Drug: Vormatrigine
• Goal: RWE Generation

SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient health data, and Praxis Precision Medicines, Inc., today announced the expansion of a successful partnership to accelerate clinical trials, data collection, and real-world evidence (RWE) generation across Praxis's clinical development programs.

Supporting the ENERGY Program for Epilepsy

Building on early success in Praxis’s innovative Essential3 Program for Essential Tremor, SEQSTER's platform continues to support the broader ENERGY program, Praxis's comprehensive program advancing vormatrigine for the treatment of epilepsy.

SEQSTER's platform provides Praxis with automated access to patient-consented electronic health records from across the U.S. healthcare system, supporting patient screening, enrollment, and ongoing data collection for its EMPOWER observational study. The ENERGY program, which includes EMPOWER and the POWER clinical studies, has attracted approximately 5,000+ patients with epilepsy.

Leadership Perspectives

"At Praxis, we are committed to delivering life-altering treatments to patients with CNS disorders faster and more effectively than has ever been done before. SEQSTER has been a foundational element of our clinical trial execution, enabling more efficient trial enrollment while capturing the longitudinal real-world data we need to advance our programs."
— Megan Sniecinski, COO, Praxis Precision Medicines

"Praxis represents exactly the kind of innovative sponsor we built SEQSTER to support. One that understands the value of real-world data and is willing to rethink how clinical trials are conducted. We're proud to have earned their trust across multiple studies."
— Ardy Arianpour, CEO, SEQSTER

About Praxis Precision Medicines

Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through its proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™.

About SEQSTER

Founded in 2016, SEQSTER is the leading healthcare technology company that connects, collects, and refines patient-consented health data across care settings into a unified, longitudinal patient view. With 150 million patients in its regulatory-grade repository, life sciences companies can accelerate research and AI developers can train higher-quality models.